Columbia Capital’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Columbia Capital’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	$1.05M	Buy	+16,917	New	+$964K	1.15%	17

Other funds holding XBI

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $49.6B AUM 39.59% 1-Year Est. Return

Columbia Capital's XBI Position: Q4 2014 in Review

Columbia Capital opened a new position in State Street SPDR S&P Biotech ETF (XBI) in Q4 2014: 16,917 shares worth $1.05M. The stake represents 1.15% of the portfolio and ranks #17 among its holdings.

146 funds tracked by Wall St. Rank hold XBI as of Q4 2014.

Columbia Capital held 16,917 shares of State Street SPDR S&P Biotech ETF worth $1.05M as of Q4 2014.
State Street SPDR S&P Biotech ETF was a new Columbia Capital position in Q4 2014.
State Street SPDR S&P Biotech ETF made up 1.15% of Columbia Capital's portfolio in Q4 2014, its #17 holding.
146 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2014.

Based on Columbia Capital's 13F filing for Q4 2014, filed 11 Feb 2015.